Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

ClinicalTrials.gov ID: NCT05338970

Public ClinicalTrials.gov record NCT05338970. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy (HERTHENA-Lung02)

Study identification

NCT ID
NCT05338970
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Daiichi Sankyo
Industry
Enrollment
586 participants

Conditions and interventions

Interventions

  • Patritumab Deruxtecan Drug
  • Platinum-based chemotherapy Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 7, 2022
Primary completion
May 30, 2024
Completion
Jun 29, 2026
Last update posted
Jan 30, 2025

2022 – 2026

United States locations

U.S. sites
23
U.S. states
16
U.S. cities
21
Facility City State ZIP Site status
Alaska Oncology and Hematology LLC Anchorage Alaska 99508
Highlands Oncology Springdale Arkansas 72762
City of Hope Duarte California 91010
Moores Cancer Center at the UC San Diego Health La Jolla California 92037
Scripps MD Anderson Cancer Center La Jolla California 92037
USC Norris Comprehensive Cancer Center Los Angeles California 90033
Kaiser Permanente - Vallejo Medical Center Vallejo California 94589
Innovative Clinical Research Institute Whittier California 90603
Sarah Cannon/Florida Cancer Specialists - FCS South Port Charlotte Florida 33980
Emory University Atlanta Georgia 30322
St Luke's Cancer Institute Boise Idaho 83712
American Oncology Partners of Maryland Bethesda Maryland 20817
Dana-Farber Cancer Institute Boston Massachusetts 02215
Dartmouth Hitchcock Medical Center Lebanon New Hampshire 03756
Hackensack Meridian Health-Southern Ocean Medical Center Manahawkin New Jersey 08050
Memorial Sloan Kettering Cancer Center New York New York 10065
Montefiore Medical Center The Bronx New York 10467
Providence Portland Medical Center Portland Oregon 97213
Sarah Cannon Research Institute Nashville Tennessee 37203
University of Texas Southwestern Medical Center Dallas Texas 75235
Inova Schar Cancer Institute Fairfax Virginia 22031
Virginia Cancer Specialists Fairfax Virginia 22031
University of Wisconsin Carbone Cancer Center Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 159 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05338970, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 30, 2025 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05338970 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →